MeVis Medical Solutions AG

M3V

Equity

ISIN DE000A0LBFE4 / Valor 3537049

Xetra (2024-09-16)

EUR 23.00%

MeVis Medical Solutions AG
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

MeVis Medical Solutions AG was established to develop and market disease-oriented products based on scientific achievements in the field of research. The company, listed on the stock exchange since 2007, operates in the field of computer-assisted, image-based medical diagnostics and therapy. With a staff of over 140 members, MeVis Medical Solutions AG holds a 49% stake in MeVis BreastCare GmbH & Co. KG, a joint venture with Varex Imaging Deutschland AG. The company focuses on developing AI products and services for the next generation in radiology. Founded in 1997, MeVis originated from the Center for Complex Systems and Visualization at Bremen University, with Prof. Dr. Heinz-Otto Peitgen playing a significant role in its development.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

In the first half of the 2023/2024 financial year, MeVis Medical Solutions AG reported a revenue of €8,774k, showing an increase from the previous year's €8,472k. This growth was driven by a rise in the sale of licenses and stable maintenance revenue.

EBIT Increase

MeVis Medical Solutions AG's earnings before interest and taxes (EBIT) saw a significant increase, rising from €1,893k in the previous year to €2,735k in the first half of 2023/2024. This improvement was primarily due to lower expenses from currency translation.

Mammography Diagnostics Performance

The company's Mammography Diagnostics segment performed well in the first half of 2024, with an increase in license sales driven by renewed demand. The maintenance business in this segment remained stable compared to the previous year.

Lung Cancer Screening Solutions

MeVis Medical Solutions AG experienced varied results in its lung cancer screening solutions. While license sales for stand-alone and cloud-based Veolity solutions were slightly ahead of the previous year, orders for lung CAD algorithms lagged due to process changes by OEM customers.

Outlook for 2023/2024

For the 2023/2024 financial year, MeVis Medical Solutions AG expects a slight increase in sales to between €18.0m and €18.5m. The company anticipates stable EBIT in the range of €4.5m to €5.0m, driven by slight sales growth and increased personnel costs and other operating expenses.

Summarized from source with an LLMView Source

Key figures

-24.3%1Y

-29.0%3Y

-21.2%5Y

Performance

22.2%1Y

22.5%3Y

23.1%5Y

Volatility